Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 1.2% – Should You Sell?

Posted by Brenda Bartman on Oct 7th, 2026

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) shares fell 1.2% during trading on Tuesday. The company traded as low as $4.98 and last traded at $5.07. 229,367 shares were traded during mid-day trading, a decline of 27% from the average session volume of 312,362 shares. The stock had previously closed at $5.13.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen raised shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Morgan Stanley upped their price target on shares of Atea Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $7.00.

Check Out Our Latest Stock Report on Atea Pharmaceuticals

Atea Pharmaceuticals Stock Performance

The firm has a market cap of $406.66 million, a PE ratio of -2.44 and a beta of 0.39. The firm has a fifty day simple moving average of $5.25 and a two-hundred day simple moving average of $5.06.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.15. Equities analysts forecast that Atea Pharmaceuticals, Inc. will post -1.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Atea Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Atea Pharmaceuticals during the second quarter worth $40,548,000. Irenic Capital Management LP purchased a new stake in shares of Atea Pharmaceuticals during the first quarter valued at $1,623,000. Hsbc Holdings PLC grew its holdings in shares of Atea Pharmaceuticals by 7.3% in the first quarter. Hsbc Holdings PLC now owns 258,989 shares of the company’s stock worth $1,380,000 after purchasing an additional 17,715 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of Atea Pharmaceuticals in the first quarter worth about $1,133,000. Finally, Wellington Management Group LLP grew its holdings in shares of Atea Pharmaceuticals by 262.7% in the second quarter. Wellington Management Group LLP now owns 206,785 shares of the company’s stock worth $962,000 after purchasing an additional 149,776 shares during the last quarter. 86.67% of the stock is owned by institutional investors.

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral infections. The company’s research centers on small-molecule therapies designed to interfere with viral replication, with the goal of addressing diseases for which convenient and effective oral treatment options are needed.

Atea’s lead investigational product is bemnifosbuvir, an oral nucleotide polymerase inhibitor developed for the treatment of COVID-19.